Department of Pharmacology, Brain Science and Engineering Institute, CMRI, Kyungpook National University School of Medicine, 101 Dong-In, Joong-gu, Daegu, Korea.
J Neurol. 2011 Dec;258(12):2181-5. doi: 10.1007/s00415-011-6087-9. Epub 2011 May 12.
Previously, chitinase 3-like 1 (CHI3L1) protein level was increased in various inflammatory conditions and cancers. This study was aimed to evaluate the plasma CHI3L1 level as a potential prognostic biomarker for Alzheimer's disease (AD). Forty-nine patients with mild cognitive impairment (MCI), 61 patients with mild to severe AD, and 35 healthy elderly controls were recruited for this study. They were given a comprehensive neuropsychological test battery including a mini-mental status examination (MMSE), clinical dementia rating (CDR), and neuropsychiatric inventory (NPI). The CHI3L1 levels were measured using a specific enzyme-linked immunosorbent assay in the plasma and cerebrospinal fluid (CSF). A significant increase in the mean plasma level of CHI3L1 was found in early AD patients compared to control subjects and MCI patients. No significant difference was found between MCI patients and controls. There was a significant positive correlation between CHI3L1 levels and neuropsychological test scores such as CDR and NPI in MCI and early AD patients. Our results demonstrate that CHI3L1 plasma levels are elevated in early AD compared to control or MCI patients. Thus, CHI3L1 plasma levels may be useful as a biomarker, reflecting disease severity in AD patients.
先前，几丁质酶 3 样蛋白 1（CHI3L1）的蛋白水平在各种炎症和癌症中增加。本研究旨在评估血浆 CHI3L1 水平作为阿尔茨海默病（AD）的潜在预后生物标志物。本研究纳入了 49 名轻度认知障碍（MCI）患者、61 名轻度至重度 AD 患者和 35 名健康老年对照组。他们接受了包括简易精神状态检查（MMSE）、临床痴呆评定量表（CDR）和神经精神问卷（NPI）在内的全面神经心理学测试。使用特定的酶联免疫吸附试验测量血浆和脑脊液（CSF）中的 CHI3L1 水平。与对照组和 MCI 患者相比，早期 AD 患者的平均血浆 CHI3L1 水平显著升高。MCI 患者与对照组之间无显著差异。在 MCI 和早期 AD 患者中，CHI3L1 水平与 CDR 和 NPI 等神经心理学测试评分之间存在显著正相关。我们的研究结果表明，与对照组或 MCI 患者相比，早期 AD 患者的血浆 CHI3L1 水平升高。因此，CHI3L1 血浆水平可能可作为反映 AD 患者疾病严重程度的生物标志物。
